Repetitive transcranial magnetic stimulation is as effective as fluoxetine in the treatment of depression in patients with Parkinson's disease

Journal of Neurology, Neurosurgery and Psychiatry

Volumn 75, Issue 8, 2004, Pages 1171-1174

  Fregni, F ^a,c   Santos, C M ^b   Myczkowski, M L ^b   Rigolino, R ^b   Gallucci Neto, J ^b   Barbosa, E R ^b   Valente, K D ^b   Pascual Leone, A ^a   Marcolin, M A ^b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

^c BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOXETINE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DAILY LIFE ACTIVITY; DEPRESSION; DRUG EFFECT; DRUG EFFICACY; FEMALE; HUMAN; INTERMETHOD COMPARISON; MALE; MEDICAL ASSESSMENT; MENTAL HEALTH; PARKINSON DISEASE; PATIENT SELECTION; PRIORITY JOURNAL; RATING SCALE; SCORING SYSTEM; SIDE EFFECT; TRANSCRANIAL MAGNETIC STIMULATION; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; AGED; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; DEPRESSIVE DISORDER; ELECTRIC STIMULATION THERAPY; FEMALE; FLUOXETINE; HUMANS; MALE; MENTAL STATUS SCHEDULE; MIDDLE AGED; PARKINSON DISEASE; PLACEBOS; SEVERITY OF ILLNESS INDEX; TRANSCRANIAL MAGNETIC STIMULATION; TREATMENT OUTCOME;

EID: 3442894212     PISSN: 00223050     EISSN: None     Source Type: Journal    
DOI: 10.1136/jnnp.2003.027060     Document Type: Article

References (24)

1. Pascual-Leone A, Bartres-Faz D, Keenan J. Transcranial magnetic stimulation: studying the brain-behaviour relationship by induction of "virtual lesions". Philos Trans R Soc Lond B Biol Sci 1999;354:1229-38.
2. Pascual-Leone A, Rubio B, Pallardo F, et al. Rapid-rate transcranial magnetic stimulation of left dorsolateral prefrontal cortex in drug-resistant depression. Lancet 1996;348:233-7.
3. Triggs W, McCoy K, Greer R, et al. Effects of left frontal transcranial magnetic stimulation on depressed mood, cognition, and corticomotor threshold. Biol Psychiatry 1999;45:1440-6.
4. George M, Wassermann E, Williams W, et al. Changes in mood and hormone levels after rapid-rate transcranial magnetic stimulation (rTMS) of the prefrontal cortex. J Neuropsychiatry Clin Neurosci 1996;8:172-80.
5. Garcia-Toro M, Pascual-Leone A, Romera M, et al. Prefrontal repetitive transcranial magnetic stimulation as add on treatment in depression. J Neurol Neurosurg Psychiatry 2001;71:546-8.
6. Loo C, Mitchell P, Sachdev P, et al. Double-blind controlled investigation of transcranial magnetic stimulation for the treatment of resistant major depression. Am J Psychiatry 1999;156:946-8.
7. Gur E, Lerer B, Dremencov E, et al. Chronic repetitive transcranial magnetic stimulation induces subsensitivity of presynaptic serotonergic autoreceptor activity in rat brain. Neuroreport 2000;11:2925-9.
8. Ben-Shachar D, Belmaker R, Grisaru N, et al. Transcranial magnetic stimulation induces alterations in brain monoamines. J Neural Transm 1997;104:191-7.
9. Ikeguchi M, Touge T, Nishiyama Y, et al. Effects of successive repetitive transcranial magnetic stimulation on motor performances and brain perfusion in idiopathic Parkinson's disease. J Neurol Sci 2003;209:41-6.
10. Shimamoto H, Takasaki K, Shigemori M, et al. Therapeutic effect and mechanism of repetitive transcranial magnetic stimulation in Parkinson's disease. J Neurol 2001;248:11148-52.
11. Dragassvic N, Potrebic A, Damjanovic A, et al. Therapeutic efficacy of bilateral prefrontal slow repetitive transcranial magnetic stimulation in depressed patients with Parkinson's disease: an open study. Mov Disord 2002;17:528-32.
12. Starkstein S, Preziosi T, Forrester A, et al. Specificity of affective and autonomic symptoms of depression in Parkinson's disease. J Neurol Neurosurg Psychiatry 1990;53:869-73.
13. Lingjaerde O, Ahlfors UG, Bech P, et al. The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross sectional study of side effects in neuroleptic treated patients. Acta Psychiatr Scand Suppl 1987;334:1-100.
14. Sachdev P, McBride R, Loo C, et al. Effects of different frequencies of transcranial magnetic stimulation (TMS) on the forced swim test model of depression in rats. Biol Psychiatry 2002;51:474-9.
15. Wassermann E. Risk and safety of repetitive transcranial magnetic stimulation: report and suggested guidelines from the International Workshop on the Safety of Repetitive Transcranial Magnetic Stimulation, June 5-7, 1996. Electroencephalogr Clin Neurophysiol 1998;108:1-16.
16. McDonald W, Richard I, DeLong M. Prevalence, etiology, and treatment of depression in Parkinson's disease. Biol Psychiatry 2003;54:363-75.
17. Brucki S, Nitrini R, Caramelli P, et al. Suggestions for utilization of the mini-mental state examination in Brazil. Arq Neuropsiquiatr 2003;61:777-81.
18. Dell'Agnello G, Ceravolo R, Nuti A, et al. SSRIs do not worsen Parkinson's disease: evidence from an open-label, prospective study. Clin Neuropharmacol 2001;24:221-27.
19. Tollefson G, Bosomworth J, Heiligenstein J, et al. A double-blind, placebo-controlled clinical trial of fluoxetine in geriatric patients with major depression. Int Psychogeriatr 1995;7:89-104.
20. Tollefson G, Basomworth J, Heiligenstein J, et al. A double-blind, placebo-controlled clinical trial of fluoxetine in geriatric patients with major depression. The Fluoxetine Collaborative Study Group. Int Psychogeriatr 1995;7:89-104.
21. Loo C, Taylor J, Gandevia S, et al. Transcranial magnetic stimulation (TMS) in controlled treatment studies: are some "sham" forms active? Biol Psychiatry 2000;47:325-31.
22. Okabe S, Ugawa Y, Kanazawa I. 0.2-Hz repetitive transcranial magnetic stimulation has no add-on effects as compared to a realistic sham stimulation in Parkinson's disease. Mov Disord 2003;18:382-8.
23. Dannon P, Dolberg O, Schreiber S, et al. Three and six-month outcome following courses of either ECT or rTMS in a population of severely depressed individuals - preliminary report. Biol Psychiatry 2002;51:687-90.
24. Fitzgerald P, Brown T, Marston N, et al. Transcranial magnetic stimulation in the treatment of depression: a double-blind, placebo-controlled trial. Arch Gen Psychiatry 2003;60:1002-8.